Cleansing Notice

20 November 2026

Notification under s 708A(5)(e) of the Corporations Act

4DMedical Limited ACN 161 684 831 (ASX: 4DX) (**Company**) advises that it has issued 1,097,495 fully paid ordinary shares (**New Shares**) on exercise of options and restricted stock units under the Company's Long Term Incentive Plan in accordance with the Appendix 2A lodged today.

This notice is given by the Company under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

1. The New Shares were issued by the Company without disclosure to investors under Part 6D.2 of the Corporations Act on Friday, 20 November 2026.

2. The Company is providing this notice under section 708A(5)(e) of the Corporations Act.

3. As at the date of this notice, the Company, as a disclosing entity under the Corporations Act, has complied with:

   (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   (b) sections 674 and 674A of the Corporations Act.

4. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) or 708A(8) of the Corporations Act, which is required to be disclosed by the Company.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate
Investor Relations
investor.relations@4dmedical.com

Administration
Company Secretary
companysecretary@4dmedical.com

Media Enquiries
Julia Maguire
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio** and 2026 acquisition of **contextflow**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

©4DMedical Limited